Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults

Vaccine

Volumn 25, Issue 8, 2007, Pages 1503-1508

  Höhler, Thomas ^a   Groeger Bicanic, Gudrun ^a   Hoet, Bernard ^b   Stoffel, Michel ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Elderly; Hepatitis A and B; Persistence

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE SEQUENCE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SWELLING; TREATMENT RESPONSE; VACCINATION;

AGED; ANTIBODY FORMATION; COHORT STUDIES; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINES, COMBINED;

EID: 33846053494     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.10.024     Document Type: Article

References (23)

1. Stoffel M., Lievens M., Dieussaert I., Martin I., and André F. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev Vaccines 2 1 (2003) 9-14
2. Fisman D.N., Agrawal D., and Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Inf Dis 35 (2002) 1368-1375
3. Joines R.W., Blatter M., Abraham B., Xie F., De Clercq N., Baine Y., et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix™) with corresponding monovalent vaccines (Havrix™ and Engerix™-B) in adults. Vaccine 19 (2001) 4710-4719
4. Roome A.J., Walsh S.J., Cartter M.L., and Hadler J. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 270 (1993) 2931-2934
5. Bock H.L., Kruppenbacher J., Sänger R., Höbel W., Clemens R., and Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 156 (1996) 2226-2231
6. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., and Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 15 (1998) 1-8
7. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 19 (2001) 2055-2060
8. Honorati C., Mariani E., Dolzani P., and Facchini A. Biological parameters influencing the immunological response to plasma derived and recombinant hepatitis B vaccines. Ann Int Super Sanita 32 (1996) 369-374
9. Reuman P.D., Kubilis P., Hurni W., Brown L., and Nalin D. The effect of age and weight on the response to formalin inactivated alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15 (1997) 1157-1161
10. Reutter J., Bart P.A., Francioli P., Safary A., and Frei P.C. Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/hepatitis B vaccination in 242 adult volunteers. J Viral Hepatitis 5 (1998) 205-211
11. Keeffe E.B., Iwarson S., McMahan B.J., Lindsay K.L., Koff R.S., Manns M., et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27 3 (1998) 881-886
12. Van der Wielen M., Van Damme P., Chlibek R., Smetana J., and von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 24 26 (2006) 5509-5515
13. Wolters B., Junge U., Dziuba S., and Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21 (2003) 3623-3628
14. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
15. European Consensus Group on Hepatitis A Immunity. Hepatitis A booster vaccination: is there a need?. Lancet 362 (2003) 1065-1071
16. Höhler T., Reuss E., Evers N., Dietrick E., Rittner C., Freitag C.M., et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360 (2002) 991-995
17. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40(no. RR-13):1-25.
18. World Health Organization. Progress in the control of viral hepatitis: memorandum for a WHO meeting. Bull WHO 66 (1988) 443-445
19. Van Damme P., Thoelen S., Cramm M., De Groote K., Safary A., and Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long-term antibody persistence. J Med Virol 44 (1994) 446-451
20. Van Damme P., Leroux-Roels G., Law B., et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 65 (2001) 6-13
21. Thompson S., and Ruff T.A. Hepatitis B vaccination: what are the current international recommendations?. Clin Immunother 3 1 (1995) 15-26
22. Jilg W., Schmidt M., and Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 6 2 (1988) 201-207
23. European Consensus Group on Hepatitis B Immunity. Are boosters immunisations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565